Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Dow
Moodys
McKesson
Colorcon

Last Updated: June 29, 2022

CLINICAL TRIALS PROFILE FOR LEMBOREXANT


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Lemborexant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01463098 ↗ A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 Completed Eisai Inc. Phase 1 2011-10-05 Part A: The purpose of this study is to evaluate the safety and tolerability of single oral doses of E2006 administered in the morning to healthy male and female subjects. Part B: The purpose of this study is to evaluate selected pharmacodynamic (PD) parameters (e.g., polysomnographically defined sleep measures) with regard to dose response in subjects with primary insomnia following single oral dosing of E2006 in the evening approximately 30 minutes prior to the sleep period, compared with 10 mg zolpidem and placebo.
NCT02350309 ↗ Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder Completed Eisai Inc. Phase 1 2014-12-13 This is a single-dose, randomized, placebo-controlled, 3-way crossover study of 2 dosage strengths of lemborexant (5 mg and 10 mg) in participants with insomnia disorder.
NCT02583451 ↗ Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects Completed Purdue Pharma LP Phase 1 2015-11-01 This is a randomized, double-blind, placebo- and active-controlled, 4-period crossover study of lemborexant in healthy adult and elderly subjects to evaluate driving performance
NCT02583451 ↗ Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects Completed Eisai Inc. Phase 1 2015-11-01 This is a randomized, double-blind, placebo- and active-controlled, 4-period crossover study of lemborexant in healthy adult and elderly subjects to evaluate driving performance
NCT02783729 ↗ Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1) Completed Eisai Inc. Phase 3 2016-05-31 This study will be conducted to demonstrate, using polysomnography, that lemborexant 10 milligrams (mg) and 5 mg is superior to placebo on objective sleep onset as assessed by latency to persistent to sleep (LPS) after the last 2 nights of 1 month of treatment in participants 55 years and older with insomnia disorder.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lemborexant

Condition Name

Condition Name for Lemborexant
Intervention Trials
Healthy Subjects 4
Insomnia 4
Insomnia Disorder 2
Healthy Participants 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lemborexant
Intervention Trials
Sleep Initiation and Maintenance Disorders 8
Disease 4
Sleep Apnea Syndromes 2
Apnea 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lemborexant

Trials by Country

Trials by Country for Lemborexant
Location Trials
United States 93
China 16
Japan 14
Canada 8
United Kingdom 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lemborexant
Location Trials
Ohio 8
Florida 8
Georgia 7
California 7
New York 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lemborexant

Clinical Trial Phase

Clinical Trial Phase for Lemborexant
Clinical Trial Phase Trials
Phase 4 2
Phase 3 4
Phase 2 1
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lemborexant
Clinical Trial Phase Trials
Completed 16
Recruiting 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lemborexant

Sponsor Name

Sponsor Name for Lemborexant
Sponsor Trials
Eisai Inc. 17
Purdue Pharma LP 9
Eisai Co., Ltd. 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lemborexant
Sponsor Trials
Industry 29
Other 3
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Dow
Baxter
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.